Skip to main content

Novo Nordisk To Pay $2 Billion for New Weight Loss Drug

Medically reviewed by Carmen Pope, BPharm. Last updated on March 25, 2025.

By I. Edwards HealthDay Reporter

TUESDAY, March 25, 2025 -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24.

The drug, called UBT251, is being developed by United Bio-Technology (Hengqin) Co., a Chinese pharmaceutical company.

Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street Journal reported.

The company also agreed to pay royalties based on future sales.

Novo Nordisk now holds the exclusive rights to develop, manufacture and sell the drug worldwide, except in mainland China, Hong Kong, Macau and Taiwan.

UBT251 is different from Novo Nordisk’s current drugs like Ozempic and Wegovy.

The drug combines GLP-1 and GIP, which lower appetite and blood sugar, with glucagon, which helps prevent dangerously low blood sugar levels.

“The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment options that cater to the diverse needs of people living with these highly prevalent diseases,” Martin Holst Lange, executive vice president for development at Novo Nordisk, told The Wall Street Journal.

UBT251 is already approved for early clinical trials in China for adults with type 2 diabetes, fatty liver disease, chronic kidney disease and those who are overweight or obese. It is also approved for similar trials in the U.S.

The deal comes as Novo Nordisk works to expand its lineup of advanced weight-loss treatments.

Although the company’s drugs have been popular, trials of some of its experimental treatments have had mixed results.

Investors are also watching closely because of concerns over pricing in the U.S. and growing competition in the obesity drug market.

Novo Nordisk’s main rival, Eli Lilly, makes the GLP-1/GIP drug tirzepatide, sold as Zepbound and Mounjaro. Eli Lilly is also working on a next-generation drug, retatrutide,

Sources

  • The Wall Street Journal, March 24, 2025

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted March 2025

Read this next

Ultra-Processed Foods Increase Risk Of Early Death

MONDAY, April 28, 2025 -- The more ultra-processed food a person regularly eats, the higher their risk of an early death, a new evidence review has concluded. Each 10% increase...

Program Matches Breast Cancer Patients To Exercise, Rehab

MONDAY, April 28, 2025 -- Breast cancer patients fare better if they continue to exercise during their treatment, and a new program can help women get the activity they need to...

Exposure Therapy For Peanut Allergy Effective In Adults

MONDAY, April 28, 2025 -- Adults with peanut allergies can be safely treated using exposure therapy to increase their resistance, new clinical trial results show. More than...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.